AbbVie’s Humira replacement plan is working
- Skyrizi and Rinvoq have become the main answer to Humira’s patent cliff.
- Neuroscience is now a second growth engine, led by Vraylar, migraine drugs, Botox Therapeutic, and Vyalev.
- Q1 2026 revenue was $15.0 billion, up 12% as reported and 10% at constant currency.
- Aesthetics is mixed: Botox Cosmetic grew, but Juvederm is still hurt by weak consumer demand.
- The price question matters because Medicare price setting now touches Imbruvica, Vraylar, Linzess, and Botox.
The post-Humira test is being passed
AbbVie’s core story is simple: Humira is fading, but the replacement drugs are growing faster. In Q1 2026, Skyrizi sales were $4.5 billion, up 29.2% at constant currency, and Rinvoq sales were $2.1 billion, up 20.2%. Humira fell 40.3% at constant currency, but the new immunology drugs more than covered the loss.
The bull case is that AbbVie has built two real growth pillars. Immunology is the first. Neuroscience is the second, with Vraylar, Botox Therapeutic, migraine drugs, and the Parkinson’s drug Vyalev. Vyalev had Q1 2026 sales of $201 million and management said it is on track to reach blockbuster revenue this year.
The bear case is not about one problem. It is about several drags that can cap the upside. Juvederm is still weak because dermal fillers depend on consumer spending. Oncology is held back by Imbruvica, which fell 24.7% in Q1 2026 at constant currency. Medicare price setting is also spreading to important products, including Vraylar and Botox.
The latest 10-Q did not change the main view. It did add a small pipeline setback: the FDA sent a Complete Response Letter for TrenibotE, an aesthetics drug candidate, because it wanted more manufacturing information. The letter did not cite safety or efficacy concerns, so this is a watch item rather than a thesis breaker.
Blockbusters, payers, and patents
AbbVie makes money by selling branded medicines. These drugs are sold to wholesalers, distributors, government agencies, health care facilities, pharmacies, and doctors. In the United States, insurers and government programs have a lot of power over access and price.
The model works best when AbbVie launches a drug with strong clinical data, wins insurance coverage, expands it into more diseases, and protects it with patents. Skyrizi and Rinvoq show that playbook. They treat immune diseases such as psoriasis, Crohn’s disease, and ulcerative colitis.
The model breaks when patents expire, rivals copy the drug, or payers cut the price. Humira is the example. Biosimilars, which are close copies of biologic drugs, have pushed Humira sales down sharply. Medicare price setting under the Inflation Reduction Act adds another pressure point for older and high-selling drugs.
AbbVie also uses deals to fill its pipeline. That can help growth, but it adds debt and integration risk. In Q1 2026, the company generated $3.8 billion of operating cash flow, paid $3.1 billion in cash dividends, issued $8.0 billion of senior notes, and repaid $2.0 billion of a term loan.
The drugs that matter most
Skyrizi and Rinvoq
These are AbbVie’s main post-Humira immunology drugs. In Q1 2026, Skyrizi grew 29.2% and Rinvoq grew 20.2% at constant currency.
Humira
Humira is the former flagship drug, but biosimilar competition is cutting into sales. Q1 2026 Humira revenue fell 40.3% at constant currency.
Neuroscience franchise
This group includes Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev. Neuroscience revenue was up 24.3% in Q1 2026, helped by fast uptake for Vyalev.
Oncology franchise
Venclexta, Elahere, and Epkinly are growing, but Imbruvica is shrinking fast. That makes oncology a mixed area rather than a clean growth story.
Aesthetics franchise
Botox Cosmetic is the lead product, while Juvederm is the problem child. In Q1 2026, Botox Cosmetic grew 17% at constant currency, while Juvederm fell 2.9%.
ABBV-295 obesity program
ABBV-295 is an early obesity pipeline asset. If later data show strong weight loss with good tolerability, it could become a future growth pillar.
TrenibotE
TrenibotE is an aesthetics candidate for frown lines. The FDA asked for more manufacturing information in April 2026, with no safety or efficacy concerns cited.
Where Q1 2026 sales came from
AbbVie reports one global business segment, so this mix groups Q1 2026 product revenue by therapy area from the Form 10-Q product table. Immunology is still the largest pool, which makes Skyrizi and Rinvoq execution very important.
What could go wrong
Humira keeps falling faster than planned
Medium impact · High oddsHumira is already in steep decline because biosimilars are taking share. In Q1 2026, Humira revenue was $688 million, down 40.3% at constant currency. The risk is that payer access gets worse and the cash flow bridge from Humira shrinks faster than AbbVie expects.
Medicare price setting hits more profit pools
High impact · High oddsImbruvica is already feeling pressure from government-set Medicare prices. The 2025 10-K also said Vraylar, Linzess, and Botox were selected for price setting between 2026 and 2028. This matters because Vraylar and Botox sit inside AbbVie’s growth and cash flow base.
Skyrizi and Rinvoq face tougher rivals
High impact · Medium oddsSkyrizi and Rinvoq are carrying the post-Humira story. If rivals take share in inflammatory bowel disease or other immune conditions, AbbVie’s growth math gets harder. The company is trying to defend its lead with new indications and easier dosing, including Skyrizi subcutaneous induction for Crohn’s disease.
Aesthetics stays weak
Medium impact · High oddsAesthetics depends partly on consumers choosing to spend on procedures. That makes it more exposed to weak consumer sentiment than the prescription drug business. Juvederm revenue fell 2.9% at constant currency in Q1 2026 because of lower demand.
Pipeline or regulatory misses slow the next leg
Medium impact · Medium oddsAbbVie needs new drugs to replace older ones over time. The TrenibotE FDA letter shows that even non-safety issues can delay launches. The bigger long-term question is whether obesity asset ABBV-295 can stand out against strong rivals already in the market.
Debt and cash returns limit flexibility
Medium impact · Medium oddsAbbVie produces large cash flow, but it also pays a large dividend and uses debt for funding. In Q1 2026, operating cash flow was $3.8 billion and cash dividend payments were $3.1 billion. The company also issued $8.0 billion of senior notes during the quarter.
In one breath
Is AbbVie still dependent on Humira?
Much less than before. Humira is still meaningful, but Skyrizi and Rinvoq are now much larger growth drivers and are offsetting the Humira decline.
Why is AbbVie’s valuation score not higher?
The business is executing well, but the stock also has visible risks. Medicare price setting, Humira erosion, debt, and weak aesthetics demand all limit how much investors may want to pay.
What is the biggest catalyst for AbbVie over the next year?
The main catalyst is execution against raised 2026 guidance. Investors will also watch Vyalev’s sales ramp, ABBV-295 obesity data, and any sign that Juvederm stabilizes.
What does a Complete Response Letter mean for TrenibotE?
It means the FDA did not approve the application in its current form. For TrenibotE, the FDA asked for more manufacturing information and did not cite safety or efficacy concerns.